Milestone Pharmaceuticals
Yahoo Finance • 2 months ago
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public Offering Raised Tot... Full story
Yahoo Finance • 3 months ago
Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has initiated an underwritten public offering of its common shares, Series A and Series B warrants for purchasing common shares, and, for certain investors, pre-funded warrants in place of... Full story
Yahoo Finance • 3 months ago
Milestone Pharmaceuticals prices $52.5 million public offering
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company with a market capitalization of $118 million, has priced its previously announced underwritten public offering at $1.50 per share, expected to r... Full story
Yahoo Finance • 3 months ago
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medic... Full story
Yahoo Finance • 3 months ago
Milestone Pharmaceuticals stock plunges on public offering announcement
Investing.com -- Milestone Pharmaceuticals Inc (NASDAQ:MIST) stock tumbled 30% after the company announced plans for an underwritten public offering of common shares and warrants. The biopharmaceutical company said it will offer common... Full story
Yahoo Finance • 3 months ago
Milestone Pharmaceuticals Announces Proposed Public Offering
MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common sha... Full story
Yahoo Finance • 3 months ago
Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Mi... Full story
Yahoo Finance • 4 months ago
Milestone Pharmaceuticals submits response to FDA for PSVT drug
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a $109.52 million market cap biotech company trading at $1.65 per share, has submitted its response to the U.S. Food and Drug Administration’s Complete Response Letter rega... Full story
Yahoo Finance • 5 months ago
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq:... Full story
Yahoo Finance • 6 months ago
FDA Issues Complete Response Letter for Etripamil for PSVT
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmac... Full story
Yahoo Finance • 7 months ago
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025 Milestone well-capitalized to com... Full story
Yahoo Finance • 7 months ago
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 94,000 optio... Full story
Yahoo Finance • last year
Milestone Pharmaceuticals Refreshes Board of Directors
Milestone Pharmaceuticals Inc. – Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -... Full story
Yahoo Finance • 2 years ago
Individual investors account for 48% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 38%
Key Insights Significant control over Milestone Pharmaceuticals by individual investors implies that the general public has more power to influence management and governance-related decisions 50% of the business is held by the top 25 shar... Full story
